Compare Steel Dynamics Inc. (STLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Steel Dynamics Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Steel Dynamics Inc. trades at $244.37 (market cap $34.81B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Steel Dynamics Inc. is far larger — about 6.9× Travere Therapeutics Inc. Common Stock's market cap, and Steel Dynamics Inc. pays a 0.87% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Steel Dynamics Inc. for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| STLD | TVTX | |
|---|---|---|
Market Cap | $34.81B | $5.02B |
Volume | 766,251 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $282.76 | $67.52 |
52-Week Low | $142.65 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $38.42B | $5.15B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Steel Dynamics (STLD) trades at $240.63, up 0.62% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 7.83% net income margin and 17.58% ROE, with Q3 2026 earnings expected at $5.41 EPS. Recent news highlights anticipation for the upcoming earnings report on October 19, 2026.
The outlook is positive, supported by analyst consensus of a $271.17 price target and 'Moderate Buy' ratings. Risks include earnings volatility and steel market cyclicality, but revenue growth to $20.5B in 2026 and solid cash flow provide a foundation for potential upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Steel Dynamics Inc.
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
